MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
- Conditions
- Head and Neck Squamous Cell CarcinomaOral Mucositis
- Interventions
- Drug: MIT-001 plus CCRT
- Registration Number
- NCT04651634
- Lead Sponsor
- MitoImmune Therapeutics
- Brief Summary
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).
- Detailed Description
Oral mucositis associated with cancer therapy carries a significant morbidity. OM is a common complication in patients receiving CCRT used for treating HNSCC. Mucositis lesions can be painful, affect nutrition and quality of life (QoL), and have a significant economic impact. However, a definitive intervention regime has not been established. Therefore, it is essential to develop appropriate treatment.
MitoImmune Therapeutics Inc. (hereafter referred to as Sponsor) has developed MIT-001 which can scavenge abnormal levels of reactive oxygen species (ROS), enabling the cells to retain mitochondrial membrane permeability and mitochondrial function. This eventually inhibits additional ROS production, indicating that MIT-001 can prevent excessive inflammation caused by ROS. In addition, MIT-001 may possibly 1) block inflammatory cytokine production via inhibiting nuclear factor kappa B (NF kB) or inflammasome dependent pathways, 2) inhibit necrosis/necroptosis via blocking high mobility group box 1 (HMGB1) mediated cytokine production, and 3) balance regulation between T helper type 1/17 (Th1/17) and regulatory T cells.
Based on the pathophysiological progression of CCRT-associated OM, initiated by direct injury to basal epithelial cells which experience deoxyribonucleic acid (DNA) damage and increased ROS levels, Sponsor expects the prevention of OM in patients receiving CCRT of locally advanced HNSCC with MIT 001 by effectively scavenging increased ROS induced by CCRT.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Histologically confirmed HNSCC (The American joint committee on cancer [AJCC] 8th edition, Stage II, III, IVA, or IVB), involving either the oral cavity or oropharynx, or HPV-positive Stage I oropharyngeal cancer.
- Treatment plan to receive a continuous course of intensity-modulated radiation therapy (IMRT) for definitive treatment of HNSCC delivered as single daily fractions of 1.8 to 2.5 Gy with a cumulative radiation dose between 60 and 72 Gy (EQD2 of 60 to 72 Gy, α/β ratio=10): Planned radiation treatment fields must include at least 30% of oral cavity that are planned to receive a total of 50 Gy or higher.
- CCRT plan to receive standard cisplatin monotherapy: Standard cisplatin monotherapy administered weekly (30 to 40 mg/m2), once per week for 5 to 7 continuous weeks.
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 1 or less
- Serum pregnancy test negative for women of childbearing potential (woman of childbearing potential [WOCBP]
- Patients who have active mucositis at screening.
- Planned to receive Erbitux™ (Cetuximab) or other targeted or immune therapy during the study.
- Tumor of the lips, sinuses, or salivary glands or unknown primary tumors.
- Metastatic disease (M1) Stage.
- Known history of severe vascular toxicity or allergies or intolerance to cisplatin and similar platinum-containing compounds.
- Any clinically significant and/or active infection, other systemic illness or condition (other than HNSCC) that would preclude them from participating in the study in the opinion of the Investigator.
- Prior resective surgery (4 weeks or less than 4 weeks from receiving surgery to randomization) for primary tumor under treatment for HNSCC.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 20 mg MIT-001 plus CCRT MIT-001 20 mg 40 mg MIT-001 plus CCRT MIT-001 40 mg 60 mg MIT-001 plus CCRT MIT-001 60 mg Placebo MIT-001 plus CCRT Matching placebo
- Primary Outcome Measures
Name Time Method Incidence of severe OM From first treatment to 2 months of safety follow-up period after CCRT completion severe OM (WHO criteria Grade 3 or higher) at a cumulative radiation dose of 60 Gy
- Secondary Outcome Measures
Name Time Method Mouth pain and discomfort From first treatment to 2 months of short-term safety follow-up period after CCRT completion Patient-reported mucositis-related mouth pain and discomfort
Analgesic use for OM From first treatment to 2 months of short-term safety follow-up period after CCRT completion Frequency and Cumulative dose (in morphine mg equivalent)
Incidence of OM From first treatment to 2 months of short-term safety follow-up period after CCRT completion Incidence of OM of each Grade (WHO criteria)
Time to onset of severe OM From first treatment to 2 months of short-term safety follow-up period after CCRT completion Time to onset of severe OM, defined as Grade 3 or higher (WHO criteria)
Trial Locations
- Locations (16)
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Cancer Center of Kansas
🇺🇸Wichita, Kansas, United States
James P. Wilmot Cancer Center
🇺🇸Rochester, New York, United States
Wake Forest Baptist Health - Comprehensive Cancer Center
🇺🇸Winston-Salem, North Carolina, United States
James Cancer Hospital Solove Research Institute
🇺🇸Columbus, Ohio, United States
The Catholic University of Korea Saint Vincent's Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
Jeonbuk National University Hospital
🇰🇷Jeonju, Jeollabuk-do, Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Hanyang University Seoul Hospital
🇰🇷Seoul, Korea, Republic of